AbbVie’s HUMIRA® (adalimumab) receives U.S. FDA approval for the treatment of pediatric patients with moderately to severely active Crohn’s disease
26 September 2014 | By AbbVie
AbbVie announced that the U.S. Food and Drug Administration has approved HUMIRA® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough...